Shipped cold to your door  ·  Lyophilized vialsQuestions? WhatsApp +62 811 2120 5090
Wellness

Retatrutide vs tirzepatide: different pathways and status

3 November 2026

Retatrutide and tirzepatide are both peptides that mimic the gut hormones regulating satiety and blood sugar, and both were developed by Eli Lilly. The difference lies in the number of receptors targeted: tirzepatide works on two receptors, GLP-1 and GIP, while Retatrutide adds a third receptor, glucagon. That is why Retatrutide is often called the next generation of the same family.

A summary of the differences

TirzepatideRetatrutide
Target receptorsGLP-1 and GIPGLP-1, GIP, and glucagon
NicknameDual agonistTriple agonist
Brand nameMounjaro and ZepboundStill uses the compound name
Development stageOn the market as a medicine in the United States since 2022, then Europe and many other countriesPhase 3 clinical trials (the TRIUMPH program)
Research focusBlood sugar, body weight, sleep apneaBody weight, liver fat, energy expenditure
Tirzepatide and Retatrutide in one table

How tirzepatide works: two pathways at once

Tirzepatide binds to the GLP-1 and GIP receptors, two incretin hormones released by the gut after eating. GLP-1 helps release insulin in line with blood sugar levels, slows gastric emptying, and sends a fullness signal to the brain. GIP also strengthens the insulin response and plays a role in how the body stores and uses fat. The combination of these two pathways is what made tirzepatide stand out in metabolic research, until it finally reached the market as a type 2 diabetes medicine under the name Mounjaro and for weight management under the name Zepbound.

What Retatrutide adds through the glucagon receptor

Retatrutide carries the same two pathways, then adds the glucagon receptor. Glucagon is better known as the hormone that raises blood sugar, but in the liver and fat tissue it also promotes fat burning and energy expenditure. In the Retatrutide formulation, the effect of glucagon on blood sugar is balanced by GLP-1 and GIP, so what is put to use is its push toward energy expenditure.

The phase 2 clinical trial of Retatrutide published in the New England Journal of Medicine in June 2023 observed large weight loss over 48 weeks, and its follow-up analysis recorded that participants' liver fat levels also went down. This finding is what made Retatrutide so widely discussed, because its third pathway touches the energy-burning side, not only satiety.

Where the research on each stands now

Tirzepatide has passed through every stage of drug development. The SURPASS clinical trial program for diabetes and SURMOUNT for body weight became the basis of its marketing authorization in the United States since 2022, followed by Europe and many other countries.

Retatrutide is in the final stage. Since December 2025, Eli Lilly has begun reporting positive results from the phase 3 clinical trial program called TRIUMPH, and the next step is applying for marketing authorization as a medicine with the relevant authorities. While that process is under way, Retatrutide is available as a research material. An explanation of each stage of its development is in Retatrutide in Indonesia.

Retatrutide as a development of the same family

For those of you who already know tirzepatide, Retatrutide is easiest to understand as a development with one additional pathway. Its two incretin pathways are the same, while the glucagon pathway adds the energy expenditure side. Peptivia also offers Retatrutide paired with Cagrilintide, an amylin pathway peptide that also helps regulate satiety; the reasons the two are paired are covered in Retatrutide and Cagrilintide, and the amylin pathway itself is reviewed in Eloralintide and the amylin pathway.

Details of the vial sizes and package contents of Retatrutide and Retatrutide + Cagrilintide are in the Peptivia catalog. If there is anything you would like to ask before ordering, the Peptivia team is ready to help through Peptivia's official WhatsApp.

Frequently asked questions
What is the difference between Retatrutide and tirzepatide?

Tirzepatide works on two receptors, GLP-1 and GIP. Retatrutide works on three receptors, GLP-1, GIP, and glucagon. This additional glucagon pathway is what is being studied for promoting energy expenditure and fat burning in the liver.

Why is Retatrutide called a triple agonist?

Because a single Retatrutide molecule is designed to bind to three hormone receptors at once: GLP-1, GIP, and glucagon. Tirzepatide, which binds to two receptors, is called a dual agonist.

Is Mounjaro the same as tirzepatide?

Yes. Mounjaro is the brand name of tirzepatide for type 2 diabetes, while Zepbound is the brand name of the same tirzepatide for weight management.

Are Retatrutide and tirzepatide made by the same company?

Yes, both were developed by Eli Lilly. Tirzepatide is already marketed as Mounjaro and Zepbound, while Retatrutide is still known by its compound name while the phase 3 clinical trials are ongoing.

Peptides in this article

Still deciding which one fits? Tell us your goal and we will help you narrow it down.

Chat on WhatsApp